Almac Sciences has expanded its continuous processing platform with the launch of a new cGMP‑-compliant flow hydrogenation capability, advancing its API development and manufacturing offering. This high‑-pressure system brings enhanced control, safety, and efficiency to one of the most widely used transformations in modern synthetic chemistry and is now available to support both clinical and commercial programs.
The investment builds on more than eight years of focused development in flow chemistry, including extensive experience in packed‑-bed hydrogenation at scales exceeding 100 kg. The addition of cGMP capability represents a major step forward, enabling seamless progression from early development to commercial manufacture while supporting stronger process performance and consistency.
The new platform integrates with Almac Sciences’ established strengths in cryogenic organometallic chemistry, packed‑-bed hydrogenation, and continuous processing. Together, these technologies deliver significant operational and environmental benefits, including reduced solvent volumes, lower catalyst consumption, faster cycle times, and improved energy efficiency. These advantages support both sustainability goals and cost‑-effectiveness, offering clients a more streamlined and resource‑-efficient manufacturing pathway.
As demand grows for safer, greener, and more flexible manufacturing solutions, Almac Sciences’ new cGMP flow hydrogenation is well positioned to meet evolving industry needs. The investment strengthens the company’s continuous flow offering and provides global partners with advanced technologies backed by multidisciplinary expertise, ensuring high‑-quality API delivery and long‑-term manufacturing confidence.
